About John Foglesong
Form D filings for Grannus Therapeutics from 2022 to 2024 list John Foglesong as CEO and director.
John Foglesong first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name John Foglesong in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people John Foglesong works with at each company, as listed on that company's latest Form D.
Grannus Therapeutics, Inc. · Form D, Jan 12, 2024
BB
Brian Blagg
Director